Axa S.A. Spring Works Therapeutics, Inc. Call Options Transaction History
Axa S.A.
- $32.2 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SWTX
# of Institutions
236Shares Held
67.2MCall Options Held
260KPut Options Held
316K-
Vanguard Group Inc Valley Forge, PA7.16MShares$399 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.62MShares$313 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.46MShares$193 Million5.51% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.27MShares$183 Million0.01% of portfolio
-
State Street Corp Boston, MA3MShares$167 Million0.0% of portfolio
About SpringWorks Therapeutics, Inc.
- Ticker SWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,401,100
- Market Cap $3.48B
- Description
- SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...